Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer

F. A. Greco, P. B. Murphy, J. D. Hainsworth, K. R. Hande, D. H. Johnson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Etoposide is a highly schedule-dependent agent. We previously reported that a 21-day schedule of oral etoposide had good activity in small cell lung cancer (SCLC). The current phase II study was designed to test the combination of 21-day oral etoposide with cisplatin in hopes of capitalizing on etoposide's schedule dependency. Sixteen extensive stage SCLC patients were treated with cisplatin 100 mg/m2 day 1 plus 21 days of low-dose oral etoposide 50 mg/m2/day. Chemotherapy was repeated every 28 days for 4 cycles. Blood counts were monitored weekly, and etoposide was discontinued if the leukocyte or platelet count dropped below 2.0 x 109/l or 75 x 109/l, respectively. Fifteen of 16 patients were evaluable for response; 13 achieved either a complete (13%) or partial response (73%), for an overal] response rate of 86% (95% confidence interval, 62-93%). Median response duration was approximately 7 months; median survival was not reached. Thirteen patients (81%) received all the planned cycles of chemotherapy. In cycle 1 of chemotherapy, the median leukocyte nadir was 2.8 x 109/l (range, 0.1-6.3 x 109/l; median platelet nadir was 180 x 109/1 (range, 51-397 x 109/l). Life-threatening leukopenia (< 1.0 x 109/l) was unusual (2 of 58 cycles). There was 1 treatment-related death. One patient developed mild renal insufficiency that resolved after therapy. Nonhematologic toxicities were uncommon, but alopecia occurred in all patients. These data do not suggest that a major survival benefit will be derived for patients with extensive stage SCLC by increasing the duration of etoposide administration when used in combination with cisplatin. A randomized study is needed to determine if this long-term schedule of etoposide plus cisplatin is superior to the standard schedule of etoposide plus cisplatin.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalOncology
Volume49
Issue numberSUPPL. 1
StatePublished - 1992

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cisplatin
Oral Administration
Appointments and Schedules
Drug Therapy
Survival
Alopecia
Leukopenia
Platelet Count
Leukocyte Count
Renal Insufficiency
Leukocytes
Blood Platelets
Confidence Intervals
Therapeutics

Keywords

  • Etoposide
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Greco, F. A., Murphy, P. B., Hainsworth, J. D., Hande, K. R., & Johnson, D. H. (1992). Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. Oncology, 49(SUPPL. 1), 34-39.

Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. / Greco, F. A.; Murphy, P. B.; Hainsworth, J. D.; Hande, K. R.; Johnson, D. H.

In: Oncology, Vol. 49, No. SUPPL. 1, 1992, p. 34-39.

Research output: Contribution to journalArticle

Greco, FA, Murphy, PB, Hainsworth, JD, Hande, KR & Johnson, DH 1992, 'Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer', Oncology, vol. 49, no. SUPPL. 1, pp. 34-39.
Greco, F. A. ; Murphy, P. B. ; Hainsworth, J. D. ; Hande, K. R. ; Johnson, D. H. / Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. In: Oncology. 1992 ; Vol. 49, No. SUPPL. 1. pp. 34-39.
@article{7f77fab0c65a496ba8bbc38ba18e267e,
title = "Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer",
abstract = "Etoposide is a highly schedule-dependent agent. We previously reported that a 21-day schedule of oral etoposide had good activity in small cell lung cancer (SCLC). The current phase II study was designed to test the combination of 21-day oral etoposide with cisplatin in hopes of capitalizing on etoposide's schedule dependency. Sixteen extensive stage SCLC patients were treated with cisplatin 100 mg/m2 day 1 plus 21 days of low-dose oral etoposide 50 mg/m2/day. Chemotherapy was repeated every 28 days for 4 cycles. Blood counts were monitored weekly, and etoposide was discontinued if the leukocyte or platelet count dropped below 2.0 x 109/l or 75 x 109/l, respectively. Fifteen of 16 patients were evaluable for response; 13 achieved either a complete (13{\%}) or partial response (73{\%}), for an overal] response rate of 86{\%} (95{\%} confidence interval, 62-93{\%}). Median response duration was approximately 7 months; median survival was not reached. Thirteen patients (81{\%}) received all the planned cycles of chemotherapy. In cycle 1 of chemotherapy, the median leukocyte nadir was 2.8 x 109/l (range, 0.1-6.3 x 109/l; median platelet nadir was 180 x 109/1 (range, 51-397 x 109/l). Life-threatening leukopenia (< 1.0 x 109/l) was unusual (2 of 58 cycles). There was 1 treatment-related death. One patient developed mild renal insufficiency that resolved after therapy. Nonhematologic toxicities were uncommon, but alopecia occurred in all patients. These data do not suggest that a major survival benefit will be derived for patients with extensive stage SCLC by increasing the duration of etoposide administration when used in combination with cisplatin. A randomized study is needed to determine if this long-term schedule of etoposide plus cisplatin is superior to the standard schedule of etoposide plus cisplatin.",
keywords = "Etoposide, Small cell lung cancer",
author = "Greco, {F. A.} and Murphy, {P. B.} and Hainsworth, {J. D.} and Hande, {K. R.} and Johnson, {D. H.}",
year = "1992",
language = "English (US)",
volume = "49",
pages = "34--39",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer

AU - Greco, F. A.

AU - Murphy, P. B.

AU - Hainsworth, J. D.

AU - Hande, K. R.

AU - Johnson, D. H.

PY - 1992

Y1 - 1992

N2 - Etoposide is a highly schedule-dependent agent. We previously reported that a 21-day schedule of oral etoposide had good activity in small cell lung cancer (SCLC). The current phase II study was designed to test the combination of 21-day oral etoposide with cisplatin in hopes of capitalizing on etoposide's schedule dependency. Sixteen extensive stage SCLC patients were treated with cisplatin 100 mg/m2 day 1 plus 21 days of low-dose oral etoposide 50 mg/m2/day. Chemotherapy was repeated every 28 days for 4 cycles. Blood counts were monitored weekly, and etoposide was discontinued if the leukocyte or platelet count dropped below 2.0 x 109/l or 75 x 109/l, respectively. Fifteen of 16 patients were evaluable for response; 13 achieved either a complete (13%) or partial response (73%), for an overal] response rate of 86% (95% confidence interval, 62-93%). Median response duration was approximately 7 months; median survival was not reached. Thirteen patients (81%) received all the planned cycles of chemotherapy. In cycle 1 of chemotherapy, the median leukocyte nadir was 2.8 x 109/l (range, 0.1-6.3 x 109/l; median platelet nadir was 180 x 109/1 (range, 51-397 x 109/l). Life-threatening leukopenia (< 1.0 x 109/l) was unusual (2 of 58 cycles). There was 1 treatment-related death. One patient developed mild renal insufficiency that resolved after therapy. Nonhematologic toxicities were uncommon, but alopecia occurred in all patients. These data do not suggest that a major survival benefit will be derived for patients with extensive stage SCLC by increasing the duration of etoposide administration when used in combination with cisplatin. A randomized study is needed to determine if this long-term schedule of etoposide plus cisplatin is superior to the standard schedule of etoposide plus cisplatin.

AB - Etoposide is a highly schedule-dependent agent. We previously reported that a 21-day schedule of oral etoposide had good activity in small cell lung cancer (SCLC). The current phase II study was designed to test the combination of 21-day oral etoposide with cisplatin in hopes of capitalizing on etoposide's schedule dependency. Sixteen extensive stage SCLC patients were treated with cisplatin 100 mg/m2 day 1 plus 21 days of low-dose oral etoposide 50 mg/m2/day. Chemotherapy was repeated every 28 days for 4 cycles. Blood counts were monitored weekly, and etoposide was discontinued if the leukocyte or platelet count dropped below 2.0 x 109/l or 75 x 109/l, respectively. Fifteen of 16 patients were evaluable for response; 13 achieved either a complete (13%) or partial response (73%), for an overal] response rate of 86% (95% confidence interval, 62-93%). Median response duration was approximately 7 months; median survival was not reached. Thirteen patients (81%) received all the planned cycles of chemotherapy. In cycle 1 of chemotherapy, the median leukocyte nadir was 2.8 x 109/l (range, 0.1-6.3 x 109/l; median platelet nadir was 180 x 109/1 (range, 51-397 x 109/l). Life-threatening leukopenia (< 1.0 x 109/l) was unusual (2 of 58 cycles). There was 1 treatment-related death. One patient developed mild renal insufficiency that resolved after therapy. Nonhematologic toxicities were uncommon, but alopecia occurred in all patients. These data do not suggest that a major survival benefit will be derived for patients with extensive stage SCLC by increasing the duration of etoposide administration when used in combination with cisplatin. A randomized study is needed to determine if this long-term schedule of etoposide plus cisplatin is superior to the standard schedule of etoposide plus cisplatin.

KW - Etoposide

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0026736416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026736416&partnerID=8YFLogxK

M3 - Article

C2 - 1323810

AN - SCOPUS:0026736416

VL - 49

SP - 34

EP - 39

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - SUPPL. 1

ER -